Brain Metastases: Staging and Treatment

Autor: Marisa Healy, BSN, RN
Fecha de la última revisión: November 10, 2023

What is staging for cancer?

Staging is the process of learning how much cancer is in your body and where it is. Brain metastases (brain mets) themselves are not staged, but they will affect the stage your primary cancer (where the cancer started). For more details about the stage of your cancer, please see the staging for your primary cancer type.

If your provider thinks you may have brain mets, they will order imaging studies, such as an MRI and CT scan to look at your brain. You may need a biopsy if the primary cancer type is unknown or if it has been a long time since your treatment for the initial primary cancer and your new symptoms.

Treatment Options

Treatment for brain mets depends on many factors, like your primary cancer stage and what treatments you are getting, your age, overall health, and number of brain mets. Your treatment may include some or all of the following:

Each primary cancer acts and is treated differently. The treatment options for brain mets depend on your primary tumor type.

Symptom Management with Corticosteroids

Your skull is hard and meant to protect your brain. Inside your skull there is not much extra space. Brain metastases take up space in the brain, putting pressure on nearby tissue. This pressure can cause symptoms. The first goal of treatment is to relieve some of this pressure by decreasing swelling. To do this, medications called corticosteroids are used (dexamethasone, prednisone). They can be given by mouth (orally) or through an intravenous (IV, into a vein) catheter. Some people feel better soon after starting steroids. However, this does not mean the tumor is gone. You may also be given medication to treat or prevent seizures.


Surgery can be used to treat one met (lesion), especially if the cancer is under control in the rest of your body. The lesion must be in an area of the brain where it is safe to have surgery. Studies have shown that patients with a single brain metastasis who had surgery followed by whole brain radiation therapy (WBRT) have fewer recurrences (when the cancer comes back) and better quality of life than patients treated with WBRT alone.

Whole Brain Radiation Therapy

Whole brain radiotherapy (WBRT) is radiation given to the entire brain. WBRT:

  • Is often given in 10 to 15 doses (also called fractions).
  • Is often used when surgery is not an option or when there are more than 3 brain mets.
  • WBRT may also be used with stereotactic radiosurgery/SRS (see below).

The whole brain is treated because there may be cancer cells in the brain, but not enough of them yet to form a met that is seen on a CT or MRI. Treatment of the whole brain tries to kill all the cancer cells, even those that haven’t formed an actual met.

WBRT improves symptoms of brain metastases in 70-90% of patients, although some of this is also a result of the corticosteroids. Recurrence is common, and control of brain metastases may only happen in half of the patients. Patients with tumors that are more sensitive to the effects of radiation respond better (lung and breast, for example) than those with tumors that are less sensitive to radiation (melanoma and renal cancers).

Stereotactic Radiosurgery (SRS)

Stereotactic radiosurgery (SRS) is not surgery. It is a large dose of radiation to the tumor given in a very precise way. Your head needs to be kept very still using a helmet or mask so that you don’t move during treatment.

SRS is given in a single dose (Gamma Knife®) or up to five doses (Cyberknife®). More than one brain met can be treated during one session. For example, if you have 2 brain metastases, both could be treated on the same day. Treatments are given by a traditional radiation machine called a linear accelerator, or a machine such as Gamma Knife®, Cyberknife®, XKnife® and ExacTrac®.

Gamma Knife® delivers several hundred beams of radiation from a cobalt source. The radiation beams concentrate at the point where all the beams meet (see picture). The radiation beams travel through hundreds of holes in the helmet. This lets a high dose of radiation to be delivered to the tumor while protecting the surrounding tissue from the high dose.

XKnife® is a linear accelerator-based treatment. Like Gamma Knife, a head frame is used, which will remain on for the entire treatment.

Cyberknife® is a form of frameless SRS using a specialized miniature linear accelerator with a robotic arm. Instead of using a frame to keep you still a custom mask is used for each patient along with skull-based tracking, allowing the robot to follow a target. Cyberknife® can also treat lesions larger than 3 cm and be used in other parts of the body.

Proton therapy is a newer form of SRS. A machine called a synchrotron or cyclotron speeds up the protons and delivers them to the tumor. The high energy of these moving protons can kill cancer cells. During treatment, the protons can precisely target the tumor. Proton therapy is often given 5 days a week for about 4 to 8 weeks. Your care team will talk with you about the best radiation option(s) and will make a care plan based on your case.


Chemotherapy is the use of anti-cancer medications to treat cancer. It is believed that most chemotherapy medications are not able to enter the brain. This is because of something called the blood-brain barrier. These medications can travel through the bloodstream but can’t get into the brain. However, sometimes chemotherapy can make it to the brain.

It has been found that brain mets that come from primary tumors that respond well to chemotherapy (such testicular cancer, lymphomas, and small cell lung cancer) are also sensitive to chemotherapy. Research has also shown that people who have not had a large amount of chemotherapy in the past may have a better response with chemotherapy treatment for their brain mets. This leads researchers to believe that some chemotherapies pass through the blood-brain barrier, just not always in effective amounts. One chemotherapy medication, temozolomide (Temodar®), is an oral medication that is capable of crossing the blood-brain barrier. It can be used to treat some brain mets.

Targeted Therapy

These therapies target specific changes on a cell that help cancer grow and spread. Your tumor will be tested for these specific targets.

There are many targeted therapies that can be used in the treatment of brain mets because they also target the primary tumor. Some targeted therapies used in the treatment of brain mets are lapatinib, erlotinib, gefitinib, osimertinib, vemurafenib, alectinib, brigatinib, ceritinib, tucatinib, and trastuzumab, depending on where the primary tumor is.


Immunotherapy uses your body’s own immune system to find and kill cancer cells. It is also called biologic therapy. Immunotherapy medications being used to treat brain mets are ipilimumab, nivolumab, and pembrolizumab, depending on where the primary tumor is. CAR-T therapy is also being studied in clinical trials as a treatment option for brain mets in some cancer types.

To learn more about your specific cancer type and their treatment use our cancer types menu.

Clinical Trials

You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.

Making Treatment Decisions

Your care team will make sure you are included in choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.

American Association of Neurological Surgeons. Metastatic brain tumors. Taken from

American Cancer Society. About Brain and Spinal Cord Tumors in Adults. 2017. Found at:

American Society of Clinical Oncology (ASCO). 2022. Caring for a Person with a Brain Tumor or Metastatic Brain Cancer. Taken from

Amsbaugh MJ, Kim CS. Brain Metastasis. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:

Costa, D. B., Shaw, A. T., Ou, S. H. I., Solomon, B. J., Riely, G. J., Ahn, M. J., ... & Crinò, L. (2015). Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. Journal of Clinical Oncology, 33 (17), 1881-1888.

Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., ... & Ou, S. H. I. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. The Lancet Oncology, 15(10), 1119-1128.

Galldiks, N., Kocher, M., Ceccon, G., Werner, J. M., Brunn, A., Deckert, M., ... & Langen, K. J. (2020). Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-oncology, 22(1), 17-30.

Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta O, et al. (2012)Whole-brain irradiation with concomitant daily fixed-dose Temozolomide for brain metastases treatment: A randomized phase II trial. Radiotherapy and Oncology: doi:10.1016/j.radonc.2011.12.004

Gazit, I., Har-Nof, S., Cohen, Z. R., Zibly, Z., Nissim, U., & Spiegelmann, R. (2015). Radiosurgery for brain metastases and cerebral edema. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia, 22(3), 535-538.

Kondziolka, D., Kalkanis, S. N., Mehta, M. P., Ahluwalia, M., & Loeffler, J. S. (2014). It is time to reevaluate the management of patients with brain metastases. Neurosurgery, 75(1), 1-9.

Lippitz, B., Lindquist, C., Paddick, I., Peterson, D., O’Neill, K., & Beaney, R. (2014). Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treatment Reviews, 40(1), 48-59.

Nayak, L., Lee, E. Q., & Wen, P. Y. (2012). Epidemiology of brain metastases. Current Oncology Reports, 14(1), 48-54.

Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2021). Emerging Immunotherapies in the Treatment of Brain Metastases. The Oncologist, 26(3), 231-241.

Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., ... & Lin, N. U. (2014). Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 32(19), 2100-2108.

Saad, S., Wang, T. J., Jani, A., Qureshi, Y. H., Yaeh, A., Nanda, T., ... & Isaacson, S. R. (2014). BM29: Number of Brain Metastases Influences Survival Following Gamma Knife Radiosurgery. Neuro-Oncology, 16(suppl 5), v38-v38.

Sahgal, A., Aoyama, H., Kocher, M., Neupane, B., Collette, S., Tago, M., ... & Chang, E. L. (2015). Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. International Journal of Radiation Oncology, Biology, and Physics, 91(4), 710-717.

Wegner, R. E., Leeman, J. E., Kabolizadeh, P., Rwigema, J. C., Mintz, A. H., Burton, S. A., & Heron, D. E. (2015). Fractionated stereotactic radiosurgery for large brain metastases. American Journal of Clinical Oncology, 38(2), 135-139.

Wong, E., Tsao, M., Zhang, L., Danjoux, C., Barnes, E., Pulenzas, N., ... & Chow, E. (2015). Survival of patients with multiple brain metastases treated with whole-brain radiotherapy. CNS Oncology, 4(4), 213-224.

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., ... & Tsuchiya, K. (2014). Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncology, 15(4), 387-395.

Publicaciones de Blog Relacionadas

May 31, 2023

A Poet’s Autobiography of Cancer

by OncoLink Team

April 19, 2023

Happy Occupational Therapy Month

by OncoLink Team